Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced the first patient has been dosed in multiple Phase II studies of ...
siRNA therapies show promise for treating diseases like cancer and genetic disorders, but their effectiveness depends on proper delivery. A recent study found that the method of mixing siRNA with ...
However, siRNA's therapeutic potential is limited by off-target effects, which occur when the siRNAs interact with non-target mRNA strands. These unintended interactions can lead to harmful ...
siMecA-AGO2 complex inhibits the translation of the mecA gene which encodes the penicillin-binding protein 2a (PBP2a), a protein at the heart of the drug-resistance phenotype in MRSA. By reducing ...
Diagram of the image of being able to distinguish differences in the state of nucleic acids inside LNPs by evaluating their physical properties using NMR. Small interfering RNA (siRNA) molecules hold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results